Show simple item record

dc.contributor.authorTakashita, Emi
dc.contributor.authorDaniels, Rod S
dc.contributor.authorFujisaki, Seiichiro
dc.contributor.authorGregory, Vicki
dc.contributor.authorGubareva, Larisa V
dc.contributor.authorHuang, Weiijuan
dc.contributor.authorHurt, Aeron C
dc.contributor.authorLackenby, Angie
dc.contributor.authorNguyen, Ha T
dc.contributor.authorPereyaslov, Dmitriy
dc.contributor.authorRoe, Merryn
dc.contributor.authorSamaan, Magdi
dc.contributor.authorSubbarao, Kanta
dc.contributor.authorTse, Herman
dc.contributor.authorWang, Dayan
dc.contributor.authorYen, Hui-Ling
dc.contributor.authorZhang, Wenqing
dc.contributor.authorMeijer, Adam
dc.date.accessioned2020-08-16T15:47:34Z
dc.date.available2020-08-16T15:47:34Z
dc.date.issued2020-01-01
dc.identifier.issn1872-9096
dc.identifier.pmid32004620
dc.identifier.doi10.1016/j.antiviral.2020.104718
dc.identifier.urihttp://hdl.handle.net/10029/624114
dc.description.abstractThe global analysis of neuraminidase inhibitor (NAI) susceptibility of influenza viruses has been conducted since the 2012-13 period. In 2018 a novel cap-dependent endonuclease inhibitor, baloxavir, that targets polymerase acidic subunit (PA) was approved for the treatment of influenza virus infection in Japan and the United States. For this annual report, the susceptibilities of influenza viruses to NAIs and baloxavir were analyzed. A total of 15409 viruses, collected by World Health Organization (WHO) recognized National Influenza Centers and other laboratories between May 2017 and May 2018, were assessed for phenotypic NAI susceptibility by five WHO Collaborating Centers (CCs). The 50% inhibitory concentration (IC50) was determined for oseltamivir, zanamivir, peramivir and laninamivir. Reduced inhibition (RI) or highly reduced inhibition (HRI) by one or more NAIs was exhibited by 0.8% of viruses tested (n = 122). The frequency of viruses with RI or HRI has remained low since this global analysis began (2012-13: 0.6%; 2013-14: 1.9%; 2014-15: 0.5%; 2015-16: 0.8%; 2016-17: 0.2%). PA gene sequence data, available from public databases (n = 13523), were screened for amino acid substitutions associated with reduced susceptibility to baloxavir (PA E23G/K/R, PA A36V, PA A37T, PA I38F/M/T/L, PA E119D, PA E199G): 11 (0.08%) viruses possessed such substitutions. Five of them were included in phenotypic baloxavir susceptibility analysis by two WHO CCs and IC50 values were determined. The PA variant viruses showed 6-17-fold reduced susceptibility to baloxavir. Overall, in the 2017-18 period the frequency of circulating influenza viruses with reduced susceptibility to NAIs or baloxavir was low, but continued monitoring is important.en_US
dc.language.isoenen_US
dc.subjectBaloxaviren_US
dc.subjectInfluenzaen_US
dc.subjectNeuraminidase inhibitoren_US
dc.subjectResistanceen_US
dc.subjectSurveillanceen_US
dc.subjectSusceptibilityen_US
dc.titleGlobal update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.en_US
dc.typeArticleen_US
dc.identifier.journalAntiviral Res 2020; 175:104718en_US
dc.source.journaltitleAntiviral research


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record